Literature DB >> 9094705

Association between susceptibility to Theiler's virus-induced demyelination and T-cell receptor Jbeta1-Cbeta1 polymorphism rather than Vbeta deletion.

Y Y Bahk1, C A Kappel, G Rasmussen, B S Kim.   

Abstract

Theiler's murine encephalomyelitis virus (TMEV) induces demyelinating disease in susceptible mouse strains after intracerebral inoculation. The clinical symptoms and histopathology of the central nervous system appear to be similar to those of human multiple sclerosis (MS), and thus, this system provides an excellent infectious animal model for studying MS. The virus-induced demyelination is immune mediated, and the genes involved in the immune response such as those for the T-cell receptor beta-chain and major histocompatibility complex (MHC) haplotypes are known to influence disease susceptibility. To define whether the T-cell receptor Jbeta-Cbeta or Vbeta genes are associated with susceptibility, we have analyzed F2 mice from crosses of susceptible SJL/J (Vbeta(a)-JCbeta(b)) mice and resistant C57L (Vbeta(a)-JCbeta(a)) mice. Our results indicate that susceptibility to TMEV-induced demyelination is associated with restriction fragment length polymorphism reflecting the T-cell receptor Jbeta1-Cbeta1 region rather than the Vbeta polymorphism. This association becomes stronger when the MHC haplotype is considered in the linkage analysis. However, differences in the T-cell receptor alpha-chain haplotype have no significant influence on the pathogenesis of TMEV-induced demyelination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094705      PMCID: PMC191580     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex.

Authors:  K C Garcia; M Degano; R L Stanfield; A Brunmark; M R Jackson; P A Peterson; L Teyton; I A Wilson
Journal:  Science       Date:  1996-10-11       Impact factor: 47.728

2.  Variations in genetic control of susceptibility to Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. I. Differences between susceptible SJL/J and resistant BALB/c strains map near the T cell beta-chain constant gene on chromosome 6.

Authors:  R W Melvold; D M Jokinen; R L Knobler; H L Lipton
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

3.  Genomic organization and sequence of T-cell receptor beta-chain constant- and joining-region genes.

Authors:  N R Gascoigne; Y Chien; D M Becker; J Kavaler; M M Davis
Journal:  Nature       Date:  1984 Aug 2-8       Impact factor: 49.962

4.  Primary demyelination in Theiler's virus infection. An ultrastructural study.

Authors:  M C Dal Canto; H L Lipton
Journal:  Lab Invest       Date:  1975-12       Impact factor: 5.662

5.  Genetic analysis of susceptibility to Theiler's virus-induced demyelinating disease in mice.

Authors:  H L Lipton; R Melvold
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

6.  The murine T-cell receptor uses a limited repertoire of expressed V beta gene segments.

Authors:  R K Barth; B S Kim; N C Lan; T Hunkapiller; N Sobieck; A Winoto; H Gershenfeld; C Okada; D Hansburg; I L Weissman
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

7.  Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TEMV-specific delayed-type hypersensitivity.

Authors:  R J Clatch; R W Melvold; S D Miller; H L Lipton
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

8.  Demyelination induced by Theiler's virus: influence of the H-2 haplotype.

Authors:  M Rodriguez; C S David
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  Murine T-cell receptor mutants with deletions of beta-chain variable region genes.

Authors:  M A Behlke; H S Chou; K Huppi; D Y Loh
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

10.  Genetic markers of the antigen-specific T cell receptor locus.

Authors:  R Epstein; N Roehm; P Marrack; J Kappler; M Davis; S Hedrick; M Cohn
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  7 in total

1.  A spontaneous low-pathogenic variant of Theiler's virus contains an amino acid substitution within the predominant VP1(233-250) T-cell epitope.

Authors:  B S Kim; R L Yauch; Y Y Bahk; J A Kang; M C Dal Canto; C K Hall
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 2.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 3.  Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis.

Authors:  Ikuo Tsunoda; Robert S Fujinami
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-06       Impact factor: 4.147

Review 4.  Innate immune response induced by Theiler's murine encephalomyelitis virus infection.

Authors:  Byung S Kim; JoAnn P Palma; Daeho Kwon; Alyson C Fuller
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Pathogenesis of virus-induced immune-mediated demyelination.

Authors:  B S Kim; M A Lyman; B S Kang; H K Kang; H G Lee; M Mohindru; J P Palma
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  Curdlan, a Microbial β-Glucan, Has Contrasting Effects on Autoimmune and Viral Models of Multiple Sclerosis.

Authors:  Fumitaka Sato; Yumina Nakamura; Aoshi Katsuki; Sundar Khadka; Ijaz Ahmad; Seiichi Omura; Nicholas E Martinez; Ikuo Tsunoda
Journal:  Front Cell Infect Microbiol       Date:  2022-02-07       Impact factor: 5.293

Review 7.  Excessive Innate Immunity Steers Pathogenic Adaptive Immunity in the Development of Theiler's Virus-Induced Demyelinating Disease.

Authors:  Byung S Kim
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.